Harrisson S et al. Six month interim results of MSDC-0602K in a large phase 2b NASH study demonstrate significant improvement in liver enzymes and glycemic control (NCT02784444). (Abstract PS-111)
Baricitinib vermindert sterfte van ernstig zieke COVID-19-patiënten
aug 2022